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Abstract
Rationale Using biological markers to objectively measure
addiction severity or to identify individuals who might
benefit most from pro-cognitive treatment could potentially
revolutionize neuropsychopharmacology. We investigated
the use of dopamine receptor mRNA levels in circulating
blood cells as predictors of cognitive response following
dopamine agonist treatment, and as biomarkers of the
severity of stimulant drug dependence.
Methodology We employed a double-blind, placebo-
controlled cross-over design, administering a single dose
of the selective dopamine D2/3 receptor agonist pramipex-
ole (0.5 mg) to increase dopamine transmission in one
session and a placebo treatment in another session in 36
volunteers. Half the volunteers had a formal diagnosis of
stimulant dependence, while half had no psychiatric history.
Participants performed neurocognitive tests from the CAN-
TAB battery on both occasions, and stimulant-dependent
individuals rated drug craving using visual analog scales.
Whole-blood mRNA levels were measured for three
dopamine-related genes: DRD3 and DRD4 (dopamine
receptors), and catechol-O-methyltransferase (COMT; a
dopamine catabolic enzyme).
Results Stimulant users performed worse than healthy
volunteers on the cognitive tests. The variation in peripheral
dopamine D3 receptor mRNA expression explained over
one quarter of the variation in response to pramipexole on
the spatial working memory test across all participants. The
severity of stimulant dependence was also significantly
associated with peripheral COMT mRNA expression in
stimulant users.
Conclusions Peripheral expression of dopamine-related
genes may be useful as a biomarker of cognitive response
to dopamine agonist drugs and of severity of addiction to
dopamine-releasing stimulant drugs.
Keywords Peripheral biomarker . mRNA .Dopamine .
DRD3 . COMT. Spatial working memory . Stimulant
dependence . Pramipexole . Personalized medicine
Introduction
Cognitive impairments are a central feature of many neuro-
psychiatric conditions, including stimulant dependence, at-
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tention deficit hyperactivity disorder, and schizophrenia; they
are also a feature of normal aging, prompting recent
therapeutic focus on cognitive enhancement. Disease- and
age-related impairments are often particularly pronounced on
prefrontal cortex-dependent tests involving working memory.
Performance on such tests is amenable to dopaminergic
modulation (Mehta et al. 2000). However, not everybody
benefits equally from boosting dopamine transmission, as
the effects of dopaminergic agents depend on the nature of
the task and baseline dopamine neurotransmission in the
brain (Arnsten 1998). Being able to predict pharmacological
effects on tests of cognitive function could offer a promising
opportunity for neuropsychiatry, as cognitive performance is
strongly related to psychosocial functioning in patients
(Green 1996) and facilitates their retention in treatment
(Aharonovich et al. 2003).
Besides its effects on cognitive function, dopamine is
also an important modulator of motivated behavior for
natural and drug rewards (Berridge and Robinson 1998;
Everitt and Robbins 2005; Kelley and Berridge 2002;
Schultz 1997). Dopamine receptors are implicated in the
reinforcing effects of stimulant drugs such as cocaine or
amphetamines (Koob 1992; Wise and Bozarth 1987).
Despite the important role dopamine plays in addictive
behavior, it has been difficult to delineate the exact roles of
the various dopamine receptor types in drug addiction (Foll
et al. 2009). Research in experimental monkeys has shown
that chronic abuse of stimulant drugs reduces dopamine D2
receptor levels throughout the striatum (Nader et al. 2002).
Indeed, reduced D2 and D3 receptor densities, as measured
with positron emission tomography (PET), have been
documented in abstinent stimulant-dependent individuals
(SDIs). Importantly, this reduction in D2/3 receptors in the
midbrain appears to be associated with hypo-metabolism in
prefrontal cortex (PFC; Volkow et al. 1993; Volkow et al.
2001), which is likely to contribute to cognitive dysfunction
and the maladaptive behavior patterns seen in individuals
with stimulant dependence (Goldstein and Volkow 2002).
One possible pharmacological strategy would be to increase
dopamine transmission in the striatum and to reduce
symptoms of stimulant withdrawal and craving. However,
the therapeutic efficacy of dopamine agonists for this
indication has been inconsistent (Grabowski et al. 2004;
Shearer et al. 2002; Soares et al. 2004).
Dopaminergic neurotransmission in the PFC is itself
influenced by the activity of the enzyme catechol-O-methyl-
transferase (COMT), which is implicated in dopamine
catabolism (Axelrod and Tomchick 1958) and PFC-
dependent cognition (Tunbridge et al. 2004). One association
study has suggested that an interaction between COMT and
dopamine D4 receptor polymorphisms may influence the risk
for the development of stimulant abuse (Li et al. 2004). The
D4 receptor, in contrast to D2 and D3 receptors, is mainly
located in brain areas innervated by mesocortical dopamine
pathways, such as the PFC (Meador-Woodruff et al. 1996;
Tarazi and Baldessarini 1999). Since dopamine provides an
important modulatory influence on cognitive functions sub-
served by prefrontal networks, such as working memory
(Robbins and Arnsten 2009), markers of dopamine neuro-
transmission may be able to identify individuals who might
experience the greatest cognitive benefits from dopaminergic
treatment. Corroborating this idea, it was recently demon-
strated that D2/3 receptor availability in the striatum, assessed
with PET, was associated with cognitive performance
following methylphenidate administration (Clatworthy et al.
2009). These data suggest that central dopamine receptor
expression may be predictive of response to dopaminergic
drugs, but clearly, the cost, invasiveness, and radiation risk of
PET effectively preclude this technique as a routine clinical
tool for assessment of dopamine receptor status.
However, markers of dopamine receptor gene expression
in the D2-receptor family (D3 and D4 receptor subtypes) are
not only detectable in the brain but also expressed in
peripheral blood, where dopamine plays a pivotal role in
mediating communication between the nervous and im-
mune systems (Basu and Dasgupta 2000; Eskandari and
Sternberg 2002). Based on observations showing altered
dopamine receptor expression in peripheral blood cells in
patients with known abnormalities in the central dopamine
transmission (Ilani et al. 2001; Nagai et al. 1996), it has
been suggested that dopamine receptor mRNA expression
in circulating blood might reflect the dopamine receptor
level in the brain (Ilani et al. 2001) and might serve as a
useful surrogate marker for more direct measurements of
central receptor status in the brain (Gladkevich et al. 2004).
In the present study, we investigated the effects on
cognitive performance of a single dose of the selective
dopamine D2/3 agonist pramipexole (0.5 mg) in 36
volunteers, half with a diagnosis of cocaine or amphetamine
dependence and half with no history of substance abuse/
dependence. Specifically, we hypothesized that peripheral
dopamine markers (i.e., DRD3, DRD4, and COMT mRNA
levels in whole blood) would be predictive of individual
differences in performance on PFC-dependent cognitive
tests following pramipexole treatment. In individuals with
stimulant dependence, we also predicted that peripheral




Thirty-six volunteers participated in the study: 18 individ-
uals with a chronic history of stimulant drug abuse (SDIs),
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meeting the Diagnostic and Statistical Manual of Mental
Disorders-Text Revision (DSM-IV-TR; American Psychiat-
ric Association 2000) criteria for dependence on either
cocaine/crack-cocaine (n=10) or amphetamines (n=8), and
18 matched healthy controls without a history of substance
abuse/dependence. Diagnosis was ascertained using the
Structured Clinical Interview for DSM-IV (First et al. 2002).
Sixteen SDIs also met DSM-IV criteria for nicotine
dependence, two for cannabis dependence, and five for
alcohol abuse. Half the SDIs smoked cannabis regularly
(50%) and consumed other drugs sporadically (ecstasy
33%, hallucinogens 22%, benzodiazepines 6%, and opiates
6%). The non-drug-using volunteers were recruited from
the GlaxoSmithKline Clinical Unit Cambridge panel.
Eleven percent smoked cannabis sporadically, 5% were
occasional tobacco smokers, and 28% had previously
smoked tobacco. Urine samples provided by SDIs tested
positive for stimulants on each testing visit; all healthy
volunteer urine samples were negative. At a baseline
assessment, participants completed the National Adult
Reading Test (NART, Nelson 1982) to provide an estimate
of verbal IQ, the Beck Depression Inventory (BDI-II, Beck
et al. 1996) to record dysphoric mood, and the Barratt
Impulsiveness Scale (BIS-11, Patton et al. 1995) to assess
trait-impulsivity. The protocol was approved by the
Cambridge Research Ethics Committee (REC06/Q0108/
130; principal investigator: TWR). All volunteers provided
written informed consent prior to study enrolment.
Experimental procedures
We used a randomized, double-blind, placebo-controlled,
cross-over design. On each session, a single dose of
placebo or pramipexole was administered in counterbal-
anced order. Pramipexole was chosen on the basis of its
selective profile for D2/3 receptors, particularly in meso-
limbic brain areas (Catnacho-Ochoa et al. 1995; Suzuki et
al. 1998). The study also included a dopamine D2/3
antagonist intervention using amisulpride, (data reported
elsewhere: Ersche et al. 2010).
We administered pramipexole at a dose of 1.5 mg to the
first six volunteers (three SDIs and three controls). While
the SDIs tolerated this dose, this was not the case for the
controls, who were unable to perform any cognitive tests
due to nausea, vomiting, sweating, and tiredness. These
controls were subsequently administered 0.5 mg pramipex-
ole on a separate testing session, which was tolerated well.
Thereafter, all remaining participants received 0.5 mg
pramipexole. In total, we included data from 18 controls
and 18 SDIs (three of whom were administered the 1.5-mg
dose).
On each visit, participants took domperidone tablets
(30 mg) as a pre-treatment to prevent emetic side effects.
Domperidone is a peripheral D2 antagonist that does not
cross the blood–brain barrier (Champion 1988). At 2.5 and
4 h after dosing, blood samples were drawn for assessment
of drug plasma concentrations. The time elapsed between
administration of dopaminergic treatment and SDIs’ last
use of illicit stimulants was similar between the two
treatment conditions [placebo, 8.5 h (SD±5.6) and prami-
pexole 8.6 h (SD±5.7); F<1]. Approximately 180 min after
dosing, participants performed four tests from the comput-
erized Cambridge Neuropsychological Test Automated
Battery (CANTAB; www.camcog.com) and the digit-span
subtest of the Wechsler Adult Intelligence Scale (WAIS,
Wechsler 1981).
The testing sessions were separated by at least 1 week to
prevent carry-over effects, verified by the analysis of
prolactin levels in blood drawn immediately before dosing
on each testing session.
Cognitive measures
The Spatial Working Memory (SWM, Robbins et al. 1994)
test is a self-ordered search task in which participants have
to search through a spatial array of colored boxes for
tokens, without returning to a box which had already
contained a token. The number of errors was measured,
including returning to a box in which a token was already
found and returning to a box that was already found to be
empty.
Rapid Visual Information Processing (RVIP, Sahakian et
al. 1988) is a test of sustained attention, where a series of
single digits (ranging from 2 to 9) is presented one at a time
(100 digits/min) in a random order. Following a training
sequence, participants detect three-digit target sequences by
pressing the response pad. Sustained attention ability was
measured by the metric A′, a signal detection measure of
sensitivity to targets independent of the general overall
tendency to respond, calculated using both the probability
of hits and the probability of false alarms.
Paired Associates Learning (PAL, Sahakian et al. 1988)
assesses episodic memory and learning of geometric
patterns and spatial locations. Participants are shown six
boxes, and in the last trial, eight boxes, which briefly
disclose an abstract pattern. Once all the patterns have been
briefly displayed, participants are shown the patterns one at
a time and asked to select the location where they were
previously displayed. The total number of errors was
recorded.
The Information Sampling Task (IST, Clark et al. 2006)
measures the tendency to gather information prior to
making a simple probabilistic decision about which color
of a hidden two-colored five-by-five matrix is in the
majority. Prior to making the decision, participants have
the opportunity to gather as much information about the
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color of the matrix as they feel they need for making a
correct choice. The number of boxes opened, i.e., the
number of elements in the matrix which are known to the
participant at the time of decision-making, was recorded.
In the digit-span test (Wechsler 1981), participants have
to listen to an increasingly long list of digits presented for
immediate recall in either the exact order presented
(forward span) or in the reverse order (backward span).
The score reflects the maximum number of digits partic-
ipants can successfully retain in working memory. Since the
backward span has been considered to be more demanding
on working memory resources than the forward span
(Silver et al. 2003), we focused on the backward condition.
mRNA extraction and analysis
On the second testing visit, prior to drug administration, a
peripheral blood sample (2.5 ml) was drawn into PAXgene
tubes (PreAnalytiX GmbH), and total mRNA was isolated
using the PAXgene Blood RNA System (PreAnalytiX
GmbH). The use of whole blood collected into PAXgene
tubes was chosen to maximize the stability of the dopamine
receptor mRNA and to avoid potential artifactual changes
from isolating individual peripheral cell types. RNA purity
and concentration was determined by UV spectrophotom-
etry. Total RNA (400 ng in 100 μl) was reverse-transcribed
into first-strand cDNA using MultiscribeTM Reverse Tran-
scriptase (Applied Biosystems) and Oligod(T)16 primers.
Amplification of the DRD3, DRD4, and COMT target
genes was carried out using a 7900 ABI Prism Sequence
Detection System (Applied Biosystems) using 20 ng of
cDNA in 25 μl of reaction mixture by gene-specific primers
using the following Assay-on-Demand Gene Expression
Assays (Applied Biosystems); DRD3 (Hs00364455_M1),
DRD4 (Hs00609526_M1), and COMT (Hs00241349_M1),
β-actin (4333762F), GAPDH (4333764F), and cyclophilin
A (4333763F). Amplification efficiency was guaranteed for
all the aforementioned TaqMan Gene Expression assays by
Applied Biosystems (www.appliedbiosystems), and there-
fore, we did not further investigate gene expression relative
to a standard curve, which might have provided us a more
precise estimate of amplification efficacy. The PCR cycling
parameters were 50°C for 2 min, 95°C for 10 min, followed
by 40 cycles at 95°C for 15 s, and 60°C for 1 min. Relative
DRD3, DRD4, and COMT mRNA levels were calculated
using the threshold cycle for target amplification, Ct (target
gene)−average Ct value (GAPDH, β-actin and cyclophiln
A) to generate ΔCt values. The average of the three
reference genes was used for normalization since the
resulting values should be less noisy than using any
individual reference gene. However, correlations between
the single housekeeper genes suggest that our key analyses
would have been largely the same irrespective of which
control gene was used for analysis, in particular for DRD3
and DRD4 (see Supplemental Material). Correlations of the
ΔCt values with those calculated with each of the individual
reference genes were generally very high. The 2-ΔΔCt
method (Livak and Schmittgen 2001) is a convenient way
to analyze the relative changes in gene expression from
real-time quantitative PCR experiments and was calculated
for use in the analyses.
Dopamine receptor mRNA expression was not detect-
able in five samples (two SDIs, three controls); in one
control volunteer, the DRD3 level was deviated more than
eight standard deviations from the sample mean, and this
sample was therefore excluded from the analysis. We
initially wanted to extract all dopamine receptors of the
D2 family from the blood, but mRNA of the DRD2 was not
identified in our blood samples, which is consistent with
previous reports showing that DRD2 expression in the
blood is lower compared with the expression of DRD3 or
DRD4 (Kirillova et al. 2008).
Statistical analysis
Data were analyzed using the Statistical Package for the
Social Sciences 13 (SPSS Inc.). In preparation for para-
metric analyses, digit-span and PAL data were square-root
transformed to reduce skew (Howell 1997), but untrans-
formed values are displayed in the figures and tables. First,
we fitted repeated-measures analysis of co-variance models
to examine group differences in cognitive performance, the
main effect of pramipexole administration compared with
placebo, and the interaction between group and pramipex-
ole treatment. Mean BDI scores and years of education
were included as covariates.
We then focused on the associations between levels of
each of the three mRNA transcripts measured (DRD3,
DRD4, and COMT) and each of the five cognitive
measures. To summarize the influence of pramipexole
administration on cognitive performance, we calculated
change scores for each individual on each test by subtract-
ing the cognitive test scores following pramipexole from
the scores following placebo. We then examined the effects
of dopamine markers on change scores, as well as group-
by-dopamine marker interactions; these analyses also
included the effect of group. Where significant effects or
interactions of dopamine markers were identified, we then
calculated the Pearson’s correlation co-efficient r for
descriptive purposes.
Finally, we explored effects of drug treatment on
symptom severity and possible associations between dopa-
mine markers and treatment-related changes in symptom
severity in SDIs. We calculated symptom change scores as
the change in craving severity rating following pramipexole
relative to placebo, 4 h following administration, corrected
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for baseline craving level. Symptom change scores were
correlated with dopamine markers. We also estimated
correlations between dopamine marker expression levels
and baseline measures of symptom severity in the SDI
group.
Correction for multiple comparisons was performed by
dividing the initial P threshold (0.05) by 10, resulting in a
threshold of P<0.005. However, since this was an
exploratory analysis, results reaching the P<0.05 threshold
are also reported, though not commented on in the
discussion.
Results
Demographic and clinical variables
As shown in Table 1, the groups were well-matched on age,
verbal IQ, gender, and ethnicity, but SDIs had spent less
time in full-time education, and as expected from the
clinical literature (Booth et al. 2006), SDIs also scored
higher on the BDI-II than controls (Buckley et al. 2001).
Consequently, both variables were included as covariates in
the first set of analyses, though not in the analyses of
dopamine markers.
Plasma pramipexole, prolactin, and mRNA levels
There was no significant difference in plasma levels of
pramipexole between the two groups (t18.6=1.78, P>0.05),
and pramipexole plasma levels did not correlate with mean
cognitive performance following pramipexole treatment.
Prolactin levels decreased following administration of
pramipexole in both groups. At baseline (i.e., following
the pre-treatment with domperidone and prior to dosing),
there was no difference in prolactin levels between the
groups (F1,34=0.01, P=0.922) or between sessions (F1,34=
0.04, P=0.834). The groups did not differ in terms of
peripheral DRD3 (t28=0.23, P>0.05), DRD4 (t29=0.08, P>
0.05), or COMT (t29=0.49, P>0.05) mRNA levels.
Peripheral dopamine markers were unrelated to demographic
or personality variables, including years of education,
impulsivity, and depressive mood. Furthermore, we did not
identify any associations between mRNA expression and
baseline performance that survived correction for multiple
comparisons.
Effects of pramipexole and group on cognitive performance
Cognitive data are shown in Table 1. SDIs performed
significantly less accurately than controls on the SWM
(F1,32=10.14 P=0.003), digit-span (F1,31=5.00, P=0.033),
RVIP (F1,32=15.76, P<0.001), and PAL (F1,32=12.04, P=
0.002) tests and were marginally more impulsive on the IST
(F1,32=3.71, P=0.063), replicating our previous findings
(Clark et al. 2006; Ersche et al. 2006). No main effect of
pramipexole was identified on any of the measures. The
only significant drug-by-group interaction was observed on
the IST test (F1,31=6.67, P=0.015). This interaction was
driven by effects in the control participants, who performed
less impulsively following pramipexole compared with
placebo (t17=−2.29, P=0.035), while performance in the
SDI group was unaffected by pramipexole (t16=0.53, P=
0.604). Stimulant craving increased significantly in SDIs
over the course of the testing sessions (F1,17=12.2, P=
0.003), but the main effect of drug treatment (F1,17=1.33,
P>0.1) and drug-by-time interaction (F1,17=0.15, P>0.5)
were non-significant (see also Table 2).
Table 1 Demographic and baseline measures for the groups of stimulant-dependent individuals (n=18) and non-drug-taking comparison
volunteers (n=18)
Group Healthy control Stimulant-dependent F df P values
Age (years) 32.7 (±6.9) 34.3 (±7.2) 0.47 1, 34 0.498
Gender ratio (male/female) 15:3 15:3 Fisher′s exact 1.000
Ethnic ratio (Caucasian/Afro-Caribbean) 17:1 16:2 Fisher′s exact 1.000
Verbal intelligence quotient (NART) 108.4 (±6.0) 109.0 (±8.1) 0.55 1, 34 0.816
Years of education 12.4 (±1.8) 11.2 (±1.0) 6.85 1, 34 0.013
Depressive mood (BDI-II total score) 1.1 (±2.4) 9.3 (±11.1) 9.50 1, 34 0.004
Impulsivity (BIS-11 total score) 62.0 (±7.2) 82.0 (±9.5) 50.4 1, 34 <0.001
Duration of stimulant abuse (years) – 11.7 (±7,4) – – –
Compulsivity of stimulant abuse (OCDUS score) – 26.5 (±7.9) – – –
Frequency of stimulant use (times per week) – 5.4 (±2.0) – – –
NART National Adult Reading Test, BIS-11 Barratt Impulsiveness Scale, BDI-II Beck Depression Inventory, OCDUS Obsessive-Compulsive Drug
Use Scale
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Associations between peripheral dopamine markers
and pramipexole effects on cognitive test performance
Results of all regression analyses relating dopamine
biomarkers to pramipexole-induced changes in cognition
are presented in Table 3.
DRD3 We identified a significant main effect of DRD3
mRNA levels on the pramipexole-induced change in SWM
performance (F1,26=9.86, P<0.005). The group-by-DRD3
interaction was non-significant. Figure 1a illustrates this
result: individuals with lower peripheral DRD3 mRNA
levels exhibited improved accuracy on SWM performance
following pramipexole administration. For the digit-span
test, the main effect of DRD3 was non-significant, and the
group-by-DRD3 interaction did not survive correction for
multiple comparisons (F1,25=4.32, P=0.048), as shown in
Fig. S1a. For the RVIP test, the main effect of DRD3 did
not survive correction for multiple comparisons (F1,26=
4.24, P=0.05), and the group-by-DRD3 interaction was
non-significant (see Fig. S1b). On PAL and IST, no main
effects of DRD3 or interactions were identified at a
threshold of P<0.05.
DRD4 For digit-span, although the main effect of DRD4
was non-significant, there was a significant group-by-
DRD4 interaction (F1,26=11.12, P=0.003) shown in
Table 3 Pramipexole-induced performance change in controls (n=15)
and stimulant-dependent individuals (n=16)
Marker Marker×group
SWM
DRD3 F1, 26=9.86 P=0.004 F1, 26=0.71 P=0.406
DRD4 F1, 27=0.06 P=0.802 F1, 27=1.03 P=0.320
COMT F1, 27=4.21 P=0.050 F1, 27=0.20 P=0.658
Digit-span
DRD3 F1, 25=0.45 P=0.510 F1, 25=4.32 P=0.048
DRD4 F1, 26=0.001 P=0.996 F1, 26=11.12 P=0.003
COMT F1, 26=2.43 P=0.131 F1, 26=6.19 P=0.020
RVIP
DRD3 F1, 26=4.24 P=0.050 F1, 26=1.79 P=0.192
DRD4 F1, 27=0.67 P=0.419 F1, 27=0.39 P=0.539
COMT F1, 27=1.03 P=0.319 F1, 27=0.02 P=0.880
PAL
DRD3 F1, 26=0.07 P=0.788 F1, 26=0.001 P=0.991
DRD4 F1, 27=2.55 P=0.122 F1, 27=0.01 P=0.910
COMT F1, 27=1.76 P=0.196 F1, 27=1.98 P=0.171
IST
DRD3 F1, 25=0.02 P=0.901 F1, 25=0.18 P=0.672
DRD4 F1, 26=0.20 P=0.657 F1, 26=0.02 P=0.884
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Fig. S2a. Change in digit-span performance was negatively
correlated with DRD4 in SDIs (r=−0.57, P=0.017) and
positively correlated in healthy volunteers (r=0.52, P=
0.057). On the other cognitive tests, no main effects of
DRD4 or interactions were detected at a threshold of
P<0.05.
COMT For SWM, the main effect of COMT (F1,27=4.21,
P=0.050) did not survive correction for multiple compar-
isons, and the group-by-COMT interaction was non-
significant (see Fig. S2c). For digit-span, the main effect
of COMT was non-significant and the group-by-COMT
interaction, as shown in Fig. S2b, but did not survive
correction for multiple comparisons (F1,26=6.19, P=0.020).
No main effects of COMT or interactions were identified on
RVIP and IST at a threshold of P<0.05.
Associations between peripheral dopamine markers,
pramipexole effects on symptom severity, and baseline
symptom severity
The correlation between DRD4 mRNA levels and
pramipexole-induced changes in craving in the SDI group
(r=0.63, P=0.009) did not survive correction for multiple
comparisons, and no correlations with DRD3 or COMT
were identified at a threshold of P<0.05.
With regard to baseline clinical variability in the SDI
group, dopamine markers were unrelated to the duration,
frequency, or compulsivity of stimulant abuse. However,
peripheral levels of COMT mRNA were significantly
correlated with the severity of stimulant dependence, as
reflected by the number of criteria met according the DSM-
IV (r=0.78, P<0.001); see Fig. 1b.
Discussion
The results of our study provide direct experimental
evidence in support of the potential utility of peripheral
dopamine biomarkers to predict treatment response to
dopamine agonist drugs and to provide objective correlates
of variability in clinical severity of addiction to dopamine-
releasing drugs.
Peripheral dopamine markers to predict drug response
We found that peripheral D3 mRNA levels predict changes
in working memory performance following a single dose of
pramipexole. Although stimulant dependence has been
associated with cognitive impairments (Ersche and
Sahakian 2007; Rogers and Robbins 2003), the prediction
of the pramipexole-induced performance change was
independent of baseline performance or drug-taking history.
Our findings are, however, in keeping with an inverted U-
shaped function relating basal dopamine function with
performance, i.e., those individuals with relatively low
b




DRD3 mRNA levels (-2 ΔCt) in whole blood COMT mRNA levels (-2 ΔCt) in whole blood
Fig. 1 Relationships between peripheral biomarkers and cognitive/
clinical measures. a Associations between peripheral DRD3 mRNA
levels in blood cells and pramipexole-induced changes in accuracy in
working memory; b Association between peripheral COMT mRNA
levels in blood cells and severity of stimulant dependence, as reflected
by the number of DSM-IV criteria satisfied for the diagnosis of
dependence on stimulant drugs. Levels of mRNA were not detectable
in five blood samples (two stimulant users, three controls)
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DRD3 mRNA expression should improve, while partic-
ipants with relatively high peripheral expression levels
should perform worse following dopamine agonist treat-
ment. Our findings are also consistent with recent PET
studies in which dopamine D2/3 receptor binding in the
ventral striatum predicted methylphenidate-induced change
in working memory performance in healthy volunteers
(Clatworthy et al. 2009) and dopamine synthesis capacity
predicted the cognitive response to the dopamine agonist
bromocriptine (Cools et al. 2009). Given that the procedure
for obtaining peripheral dopamine markers is minimally
invasive and orders of magnitude less expensive than a PET
scan, peripheral biomarkers could be attractive for future
use in clinical practice.
The notion of predicting inter-individual variation in
the effects of dopaminergic agents on cognition and
behavior is not completely novel, although previous
attempts have depended on the use of behavioral
measures rather than peripheral biomarkers. Thus, trait-
impulsivity (Cools et al. 2007) or baseline working
memory performance (Kimberg et al. 2001) has previously
been suggested to serve as indicators for cognitive change
following dopamine agonist administration. However, the
utility of these personality or performance indicators in
psychiatric patients is questionable given that impulsivity
is a key feature of several psychiatric disorders (Moeller et
al. 2001) and cognitive impairment is common in
psychiatric conditions (Harrison and Owen 2001). By
contrast, the prediction of cognitive change by peripheral
DRD3 mRNA expression was independent of self-
reported impulsivity, mood, baseline cognitive perfor-
mance, or psychiatric status. This implies that the use of
dopamine mRNA level in circulating blood might be
particularly suitable for mental health patients.
Our findings do not support the view that abnormalities
of peripheral dopamine markers are related to the diagnosis
of stimulant dependence per se (Czermak et al. 2004), but
suggest that these markers could be used to predict
individual variability addiction severity. We found that the
higher the levels of peripheral COMT mRNA in the blood,
the more severely dependent the SDIs were. It has been
suggested that the genetic polymorphism that regulates
COMT activity in the brain may also regulate the levels of
COMT activity in lymphocytes (Sladek-Chelgren and
Weinshilboum 1981). Higher COMT activity has repeatedly
been suggested to be associated with increased vulnerability
to the development of drug abuse (Beuten et al. 2005; Li et
al. 2004; Vandenbergh et al. 1997), consistent with our
data. However, the relationship between COMT polymor-
phism and cocaine dependence has been inconsistent
(Lohoff et al. 2008). For other peripheral dopamine markers
such as the DRD3 receptor a similar relationship with
symptom severity has been identified in Parkinson’s
disease, i.e., a decrease in DRD3 mRNA levels was
associated with the degree of clinical severity in these
patients (Nagai et al. 1996). Longitudinal studies would be
needed to investigate the stability of these measures over
time, given that the severity of substance dependence may
change following therapeutic interventions.
Does expression of peripheral dopamine markers reflect
levels in the brain?
The mechanisms underlying the expression of dopamine
receptor mRNA in the brain and in the periphery are not
fully understood. It has been suggested that mRNA levels
detectable peripherally in the blood reflect levels of
expression in the brain (Caronti et al. 1998; Ilani et al.
2001; Pacheco-Lopez et al. 2003), but evidence for this
direct relationship is still lacking. While there are clear
similarities in gene expression profiles in whole blood and
brain tissue, variation in expression between tissue types
also exists (Sullivan et al. 2006). Between-subjects varia-
tion in gene expression may be driven by genetic poly-
morphisms, some of which regulate mRNA transcription,
but this regulation might also vary across different tissues.
Post-mortem analyses of stimulant users who died of a
cocaine overdose showed a significant increase in both D3
receptors (Staley and Mash 1996) and DRD3 mRNA levels
(Segal et al. 1997) in the nucleus accumbens compared with
age-matched, drug-free control brains. Unfortunately, do-
pamine markers in peripheral blood in these samples were
not analyzed, limiting direct comparison with the present
study. The current uncertainties suggest that speculations
about the comparability of gene expression peripherally and
centrally must remain tentative.
PET studies in SDIs who had been drug abstinent for
at least two weeks also showed a significant reduction
in D2/3 receptor density in the striatum compared with
non-drug-taking controls (Martinez et al. 2004; Volkow et
al. 1993). Accordingly, a separate study in a different
sample showed that peripheral dopamine receptor mRNA
expression in lymphocytes was reduced in abstinent drug
users (Czermak et al. 2004). Our SDIs had been actively
using stimulant drugs for an average of 11.7 years (SD±
7.4) and did not differ from controls in terms of peripheral
dopamine markers. One may speculate whether active
drug use increases dopamine receptor mRNA, masking a
pre-morbid down-regulation similarly to what reported for
D4 and D5 mRNA expression in opiate-dependent indi-
viduals on methadone maintenance therapy (Goodarzi et
al. 2009). Support for this view comes from de novo
patients with Parkinson’s disease, whose dopamine recep-
tor expression in lymphocytes normalized following
three months treatment with L-DOPA or a dopamine
agonist (Barbanti et al. 1999).
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Methodological issues and limitations
Our findings may differ from biomarker results reported by
other groups (Czermak et al. 2004; Goodarzi et al. 2009) as
we extracted mRNA markers from whole blood not only
from lymphocytes. We used whole blood to maximize the
stability of the dopamine receptor mRNA and to avoid
potential artifactual changes from isolating individual
peripheral cell types. We cannot rule out that the pre-
treatment with domperidone for the prevention of emetic
side effects may have affected the levels of mRNA
expression in the blood. This seems unlikely, however,
because all our participants took the same dose of
domperidone prior to drug treatment administration, and
prolactin levels, assessed immediately before dosing of
each drug treatment session, did not differ between the
groups or between the treatment sessions.
Conclusions
Our findings that peripheral D3 receptor mRNA levels
predicted individual variability in working memory follow-
ing dopamine agonist treatment suggest that such metrics
might be usefully employed in clinical practice. The ability
of peripheral biomarkers to predict response to dopamine
agonist administration could have important implications
for personalizing the treatment for psychiatric patients,
allowing clinicians to predict which patients will receive
greatest benefit from dopaminergic medications. It would
be of great interest to examine the relationship between
peripheral mRNA levels relating to neurotransmitter func-
tion and response to treatment in other neuropsychiatric
disorders. Our data also speak to the ongoing debate about
the potential utility of cognitive enhancing drugs to
optimize performance in the context of normal cognitive
variability over the lifecycle.
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